Eli Lilly’s Verzenio is already one of its fastest-growing products, but could go up another gear following a pair of FDA approvals that expand its eligible patient population – particularly ...

The FDA has approved Lilly’s Verzenio, making it the third market entrant in a new class of drugs for breast cancer. Verzenio (abemaciclib) is now licensed to treat adult patients with hormone ...

And that's where the breast cancer drug Verzenio comes in. Clinical trials have shown that for around a third of all patients with early breast cancer, the disease returns, and that even after ...